Why the study?
Despite effective LDL-lowering treatments and risk reduction strategies, patients with type 2 diabetes continue to remain at increased risk for atherosclerotic cardiovascular disease.
This review highlights the potential role of triglyceride-rich lipoproteins in the residual cardiovascular risk observed in patients with type 2 diabetes despite effective LDL-lowering therapies.
Residual ASCVD risk persists in T2D despite LDL lowering; leaves open targeted therapies beyond current strategies.
Type 2 diabetes (T2D) is a growing health concern across both developed and developing countries. Cardiovascular disease (CVD) remains the major cause of increased mortality in this patient population. In recent years, effective low density lipoprotein lowering treatments and other risk reduction strategies have substantially reduced the risk of atherosclerotic CVD, yet patients with T2D continue to remain at increased risk for atherosclerotic CVD. Here, we will briefly review various proposed underlying mechanisms for this residual risk with a more in-depth focus on the potential role of triglyceride-rich lipoproteins in residual risk and potential avenues to target this pharmacologically.
No takes yet. Share an insight, caveat, or question.
Dash et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: